BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study
- PMID: 19134192
- PMCID: PMC2626579
- DOI: 10.1186/1465-9921-10-1
BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study
Abstract
Background: Anxiety and depression are common and treatable risk factors for re-hospitalisation and death in patients with COPD. The degree of lung function impairment does not sufficiently explain anxiety and depression. The BODE index allows a functional classification of COPD beyond FEV1. The aim of this cross-sectional study was (1) to test whether the BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms; and (2) to assess which components of the BODE index are associated with these psychological aspects of COPD.
Methods: COPD was classified according to the GOLD stages based on FEV(1%predicted) in 122 stable patients with COPD. An additional four stage classification was constructed based on the quartiles of the BODE index. The hospital anxiety and depression scale was used to assess anxious and depressive symptoms.
Results: The overall prevalence of anxious and depressive symptoms was 49% and 52%, respectively. The prevalence of anxious symptoms increased with increasing BODE stages but not with increasing GOLD stages. The prevalence of depressive symptoms increased with both increasing GOLD and BODE stages. The BODE index was superior to FEV(1%predicted) for explaining anxious and depressive symptoms. Anxious symptoms were explained by dyspnoea. Depressive symptoms were explained by both dyspnoea and reduced exercise capacity.
Conclusion: The BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms in COPD patients. These psychological consequences of the disease may play a role in future classification systems of COPD.
Figures
Similar articles
-
Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study.BMC Pulm Med. 2012 Sep 10;12:53. doi: 10.1186/1471-2466-12-53. BMC Pulm Med. 2012. PMID: 22958576 Free PMC article.
-
Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease.Chin Med J (Engl). 2010 Jul;123(14):1845-51. Chin Med J (Engl). 2010. PMID: 20819566
-
Anxiety and depression in COPD patients and correlation with sputum and BAL cytology.Multidiscip Respir Med. 2011 Aug 31;6(4):226-31. doi: 10.1186/2049-6958-6-4-226. Multidiscip Respir Med. 2011. PMID: 22958450 Free PMC article.
-
Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?Int J Chron Obstruct Pulmon Dis. 2006;1(1):91-6. doi: 10.2147/copd.2006.1.1.91. Int J Chron Obstruct Pulmon Dis. 2006. PMID: 18046907 Free PMC article.
-
Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD.Respir Med. 2009 Oct;103(10):1572-9. doi: 10.1016/j.rmed.2008.11.021. Epub 2009 Jun 26. Respir Med. 2009. PMID: 19560330
Cited by
-
Smoking and pulmonary complications: respiratory prehabilitation.J Thorac Dis. 2019 Apr;11(Suppl 5):S639-S644. doi: 10.21037/jtd.2018.12.11. J Thorac Dis. 2019. PMID: 31080640 Free PMC article. Review.
-
Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease.Chron Respir Dis. 2016 Aug;13(3):220-8. doi: 10.1177/1479972316634604. Epub 2016 Mar 3. Chron Respir Dis. 2016. PMID: 26944070 Free PMC article.
-
Integrating narrative and bibliometric approaches to examine factors and impacts of tuberculosis treatment non-compliance.Multidiscip Respir Med. 2025 Feb 28;20(1):1016. doi: 10.5826/mrm.2025.1016. Multidiscip Respir Med. 2025. PMID: 40017294 Free PMC article.
-
Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study.Respir Res. 2020 Apr 15;21(1):84. doi: 10.1186/s12931-020-1328-z. Respir Res. 2020. PMID: 32293463 Free PMC article. Clinical Trial.
-
Physical Activity, Depression and Quality of Life in COPD - Results from the CLARA II Study.Int J Chron Obstruct Pulmon Dis. 2023 Nov 29;18:2755-2767. doi: 10.2147/COPD.S435278. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 38050481 Free PMC article.
References
-
- Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304. - DOI - PubMed
-
- Carrasco GP, de Miguel DJ, Rejas GJ, Centeno AM, Gobartt VE, Gil de MA, Garcia CM, Jimenez GR. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes. 2006;4:31. doi: 10.1186/1477-7525-4-31. - DOI - PMC - PubMed
-
- Gudmundsson G, Gislason T, Janson C, Lindberg E, Suppli UC, Brondum E, Nieminen MM, Aine T, Hallin R, Bakke P. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med. 2006;100:87–93. doi: 10.1016/j.rmed.2005.04.003. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical